Full text is available at the source.
Abstract
Spray-dried mRNA-lipid nanoparticle (mRNA-LNP) dry powder maintains stability for over 3 years under refrigerated conditions.
- Liquid formulations of mRNA-LNPs show significant degradation within 6-9 months, highlighting their limited stability.
- Trehalose has been identified as an effective matrix former for creating stable dry powder formulations of mRNA-LNPs.
- The dry powder platform allows for controlled particle size, low residual moisture, and preservation of lipid properties upon reconstitution.
- Reconstituted dry powder maintains in vivo protein expression comparable to liquid formulations after intravenous and intramuscular administration.
- Direct administration of dry powder enables targeted protein expression in the lungs, suggesting alternative delivery methods.
- The dry powder formulation overcomes the need for ultra-cold storage, potentially improving global accessibility to mRNA therapies.
Simplified